Processa Pharmaceuticals Inc (PCSA) — Cash Flow-to-Debt Ratio
Processa Pharmaceuticals Inc (PCSA) has a Cash Flow-to-Debt Ratio of -1.81x as of March 2026, meaning its operating cash flow of $-3.59 Million could theoretically repay -2% of its total liabilities ($1.98 Million) in one year. See PCSA financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Processa Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Processa Pharmaceuticals Inc across 15 annual periods. For the full cash flow conversion analysis, see Processa Pharmaceuticals Inc operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Processa Pharmaceuticals Inc (2011–2025)
Year-by-year debt coverage analysis for Processa Pharmaceuticals Inc. Check how high is Processa Pharmaceuticals Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.09x | $-11.39 Million | $2.24 Million | ▲ +30.6% |
| 2024 | -7.33x | $-11.25 Million | $1.53 Million | ▲ +27.5% |
| 2023 | -10.11x | $-8.06 Million | $797.48K | ▼ -21.0% |
| 2022 | -8.36x | $-9.61 Million | $1.15 Million | ▲ +6.2% |
| 2021 | -8.91x | $-8.72 Million | $978.40K | ▼ -544.8% |
| 2020 | -1.38x | $-3.14 Million | $2.27 Million | ▼ -44.2% |
| 2019 | -0.96x | $-2.75 Million | $2.87 Million | ▲ +9.2% |
| 2018 | -1.06x | $-3.71 Million | $3.51 Million | ▼ -66.4% |
| 2017 | -0.63x | $-1.65 Million | $2.61 Million | ▼ -51.5% |
| 2016 | -0.42x | $-871.91K | $2.08 Million | ▲ +0.0% |
| 2015 | -0.42x | $-871.91K | $2.08 Million | ▲ +79.3% |
| 2014 | -2.02x | $-2.70 Million | $1.33 Million | ▼ -0.8% |
| 2013 | -2.00x | $-2.54 Million | $1.27 Million | ▼ -40.4% |
| 2012 | -1.43x | $-1.89 Million | $1.32 Million | ▼ -408.7% |
| 2011 | -0.28x | $-710.00K | $2.53 Million | — |